Meisoindigo(Synonyms: 甲异靛; Dian III; N-Methylisoindigotin; Natura-α)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Meisoindigo (Synonyms: 甲异靛; Dian III; N-Methylisoindigotin; Natura-α) 纯度: 98.08%

Meisoindigo (Dian III) 是 Indirubin (HY-N0117) 的衍生物，可以造成急性髓细胞性白血病 (AML) 细胞周期在 G0/G1 期停滞，并诱导凋亡。Meisoindigo 具有很高的抗肿瘤活性。

Meisoindigo(Synonyms: 甲异靛; Dian III; N-Methylisoindigotin; Natura-α)

Meisoindigo Chemical Structure

CAS No. : 97207-47-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥2431 In-stock
2 mg ￥1600 In-stock
5 mg ￥2400 In-stock
10 mg ￥3520 In-stock
50 mg ￥8650 In-stock
100 mg ￥14500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Meisoindigo 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Drug Repurposing Compound Library
  • NMPA-Approved Drug Library
  • Medicine Food Homology Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Blood Cancer Compound Library

生物活性

Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity[1][2].

体外研究
(In Vitro)

Meisoindigo (Dian III; 5-20 μM; for 24 hours) inhibits growth of the AML cell lines[1].
Meisoindigo (10 μM; for 24 hours) induces apoptosis of acute myeloid leukemia[1].
Meisoindigo (5-10 μM; for 24 hours) causes cell-cycle arrest[1].
Meisoindigo (5-10 μM; for 24 hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells[1].
Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HL-60, NB4, U937 leukemic cell lines
Concentration: 5, 10, 15, 20 μM
Incubation Time: For 24 hours
Result: Inhibited growth of the AML cell lines in a dose- and time-dependent manner.

Apoptosis Analysis[1]

Cell Line: HL-60 cells
Concentration: 10 μM
Incubation Time: For 24 hours
Result: Induced apoptosis of acute myeloid leukemia.

Cell Cycle Analysis[1]

Cell Line: HL-60 cells
Concentration: 5, 10 μM
Incubation Time: For 24 hours
Result: Caused cell-cycle arrest, with more cells in sub-G1 and G0/G1 phases and fewer cells in the S phase, in a dose-dependent manner.

Western Blot Analysis[1]

Cell Line: HL-60 cells
Concentration: 5, 10 μM
Incubation Time: For 24 hours
Result: Increased the cleaved caspase-3 and pro-apoptotic Bak, and decreased Bcl-2 and Bcl-xL levels in HL-60 cells.

体内研究
(In Vivo)

Meisoindigo (Dian III; 50-150 mg/kg; IP; daily; for 14 days) has anti-leukemic activity in vivo[1].
Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/SCID mice, 6-8 weeks old, with HL-60 leukemic cells[1]
Dosage: 50, 100, 150 mg/kg
Administration: IP; daily; for 14 days
Result: Had anti-leukemic activity in vivo.

分子量

276.29

Formula

C17H12N2O2
CAS 号

97207-47-1
中文名称

甲异靛
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 51 mg/mL (184.59 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.6194 mL 18.0969 mL 36.1939 mL
5 mM 0.7239 mL 3.6194 mL 7.2388 mL
10 mM 0.3619 mL 1.8097 mL 3.6194 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.05 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Lee CC, et al. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Leuk Lymphoma. 2010 May;51(5):897-905.

    [2]. Yingze Ye, et al. Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway. Front Cell Neurosci. 2019 Dec 16;13:553.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务